Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00642655 · ClinicalTrials.gov registry record · Phase 1
Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation
A Phase 1 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00642655 is a Phase 1 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT00642655, a Phase 1 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and efficacy of IVIG in combination with Rituximab to lower the level of HLA-sensitive antibodies and block their ability to attack a transplanted organ in patients who are highly HLA-sensitized and are awaiting transplantation.
Interventions
- DRUG IVIG and Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00642655
The ClinicalTrials.gov registry entry for NCT00642655 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IVIG and Rituximab is the first listed.
NCT00642655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00642655 about?
NCT00642655 is a clinical study titled "Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation". The purpose of this study is to examine the safety and efficacy of IVIG in combination with Rituximab to lower the level of HLA-sensitive antibodies and block their ability to attack a transplanted organ in patients who are highly HLA-sensitized and are awaiting transplantation.
What is the current status of trial NCT00642655?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2005-09. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00642655?
The interventions under investigation include: IVIG and Rituximab (DRUG).
Who is sponsoring clinical trial NCT00642655?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.